Author Archives: Inês Martins PhD

Researchers at Washington University School of Medicine in St. Louis have been awarded $3.9 million in funding to continue developing a treatment candidate that reduces mucus production and inflammation in debilitating lung diseases, such as chronic obstructive pulmonary disease (COPD) and asthma. The award from the…

Adhering to a healthy diet — be it a Mediterranean diet, a prudent diet, or a diet supported by health associations — significantly lowers the risk of chronic obstructive pulmonary disease (COPD), a recent meta-analysis suggests. Unhealthy diets, such as the Western diet, appear to…

Smokers and people with chronic obstructive pulmonary disease (COPD) are more likely to develop severe complications and die from COVID-19 infections than infected patients who do not smoke or have COPD, a recent meta-analysis shows. This research, however, suggests that the prevalence of COPD patients and smokers among…

People with chronic obstructive pulmonary disease (COPD) have three unusual stem cell subsets in their lungs that, together, seem to contribute to the inflammation, tissue scarring, and excessive mucus secretion that characterizes the condition, a recent study has found. The research suggests that changes in lung stem cells,…

MP1032, an anti-inflammatory molecule developed by MetrioPharm, inhibits the formation of 3-nitrotyrosine — a biomarker of nitrogen reactive species — induced by cigarette smoke in the air sacs of a lung model of chronic obstructive pulmonary disease (COPD), a study has found. The research suggests that MP1032…

People with chronic obstructive pulmonary disease (COPD) are among the most vulnerable to COVID-19 infections, being even more likely to develop severe disease or to be admitted to intensive care units (ICU) than those with diseases like high blood pressure or diabetes, an analysis of several…

Patients with chronic obstructive pulmonary disease (COPD) who exhibit asthma symptoms may have poorer outcomes than other COPD patients, according to a study developed by researchers at St Paul’s Hospital in Vancouver, British Columbia. The study, “Airway hyperresponsiveness in chronic obstructive pulmonary disease: A marker of asthma-chronic obstructive pulmonary disease overlap…

Treating older adults with chronic obstructive pulmonary disease (COPD) with opioids may not be the best idea. Researchers at St. Michael’s Hospital, in Toronto, Canada, have shown that new opioid users have up to five times higher risk of death than non-opioid users. The findings were published recently in the…

GlaxoSmithKline and Innoviva announced positive data from the Phase 3 FULFIL clinical trial evaluating their investigational triple combination therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/IV) in patients with chronic obstructive pulmonary disease (COPD). FULFIL is a randomized, double-blind, multicenter study designed to evaluate the efficacy and safety of a daily dose of the FF/UMEC/IV…